TRACON Pharmaceuticals Inc (NASDAQ:TCON) Short Interest Up 66.4% in July

Share on StockTwits

TRACON Pharmaceuticals Inc (NASDAQ:TCON) was the target of a large growth in short interest in July. As of July 15th, there was short interest totalling 121,500 shares, a growth of 66.4% from the June 30th total of 73,000 shares. Based on an average daily volume of 409,100 shares, the short-interest ratio is currently 0.3 days. Currently, 2.5% of the company’s stock are sold short.

A number of institutional investors have recently made changes to their positions in TCON. Dowling & Yahnke LLC acquired a new stake in TRACON Pharmaceuticals in the 1st quarter valued at approximately $26,000. Wedbush Securities Inc. acquired a new position in shares of TRACON Pharmaceuticals during the 2nd quarter worth approximately $50,000. JPMorgan Chase & Co. acquired a new position in shares of TRACON Pharmaceuticals during the 1st quarter worth approximately $57,000. Finally, Two Sigma Investments LP acquired a new position in shares of TRACON Pharmaceuticals during the 1st quarter worth approximately $61,000. 23.02% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have recently weighed in on the company. Zacks Investment Research cut TRACON Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, June 10th. HC Wainwright cut their price objective on TRACON Pharmaceuticals from $6.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, April 24th.

NASDAQ:TCON opened at $1.65 on Friday. The business’s 50-day simple moving average is $1.92 and its 200-day simple moving average is $2.37. TRACON Pharmaceuticals has a fifty-two week low of $0.95 and a fifty-two week high of $6.10. The stock has a market capitalization of $9.08 million, a PE ratio of -0.28 and a beta of 2.06. The company has a debt-to-equity ratio of 1.23, a current ratio of 1.71 and a quick ratio of 1.71.

TRACON Pharmaceuticals (NASDAQ:TCON) last announced its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.13) by $0.35. On average, research analysts expect that TRACON Pharmaceuticals will post -3.11 earnings per share for the current year.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD.

Featured Story: Most Active Stocks

Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Berenberg Bank Reaffirms “Buy” Rating for Schindler Holding AG Participation
Berenberg Bank Reaffirms “Buy” Rating for Schindler Holding AG Participation
JPMorgan Chase & Co. Reiterates Buy Rating for Swiss Re
JPMorgan Chase & Co. Reiterates Buy Rating for Swiss Re
Shurgard Self Storage’s  “Underweight” Rating Reiterated at JPMorgan Chase & Co.
Shurgard Self Storage’s “Underweight” Rating Reiterated at JPMorgan Chase & Co.
Repay Holdings Corporation  CTO Sells $224,953.29 in Stock
Repay Holdings Corporation CTO Sells $224,953.29 in Stock
V Daniel Robinson II Sells 10,000 Shares of NBT Bancorp Inc.  Stock
V Daniel Robinson II Sells 10,000 Shares of NBT Bancorp Inc. Stock
Tantech Holdings Ltd  Sees Significant Increase in Short Interest
Tantech Holdings Ltd Sees Significant Increase in Short Interest


© 2006-2020 Ticker Report